BEA

Gonorrhea is a major global public health concern and recognized as a priority pathogen by the WHO. It is one of the most common yet disruptive diseases worldwide, with nearly 100 million cases reported annually and potentially severe health consequences like infertility, neonatal blindness, and increased risk of HIV infection.  In addition, Gonorrhea is one of the most urgent antimicrobial resistance (AMR) threats worldwide, as the bacterium Neisseria Gonorrhoeae is rapidly evolving to withstand nearly all available antibiotics. Despite the urgency, vaccine development has long been hindered by Neisseria gonorrhoeae’s ability to evade the immune system and its high genetic variability. Currently, no approved vaccines are marketed, leaving a critical gap in gonorrhea prevention and control. 

AdJane has developed BEA, a Gonorrhea vaccine based on its proprietary OMV-Vacc platform technology. The Neisseria Meningitidis bacteria –  are designed to express Neisseria Gonorrhoeae antigens on their surface that are conserved among strains and/or important for growth, and capable of inducing bactericidal antibodies, thereby ensuring broad protection and strain coverage. BEA is administered intramuscularly to elicit a strong systemic response, with the potential for intranasal application as well. Its single-component design serves as both a vaccine and an adjuvant, enhancing its immunogenic effectiveness.